Ulipristal Emergency Contraception Used Before or After Ovulation
Status:
Completed
Trial end date:
2014-04-01
Target enrollment:
Participant gender:
Summary
This was a prospective, open-label, single-drug, uncontrolled, observational clinical study.
Women attending the Family Planning Association of Hong Kong (FPAHK) for emergency
contraception within 120 hours of UPSI were recruited. Subjects were recruited from both the
Birth Control Clinics and Youth Health Care Centres of the FPAHK.
Depending on the timing in relation to ovulation in the current menstrual cycle at the time
of presentation, the women were classified into two groups:
Group 1: pre-ovulatory Group 2: post-ovulatory
After counseling and obtaining informed consent, eligible subjects received a single dose of
ulipristal acetate 30 mg (ellaOne®) under direct supervision. A baseline blood test for
hormonal profile (LH, oestradiol and progesterone) and ultrasound scan for ovarian follicle
assessment were carried out by a designated doctor or research nurse at the clinic visit.
The subjects were advised not to have further acts of coitus before the return of
menstruation. They were given a diary chart to record vaginal spotting and bleeding, possible
side effects and further acts of intercourse, if any, and the contraceptive method used. A
follow-up appointment were be arranged about 1-2 weeks after the expected next menstruation.
Any events of unplanned pregnancy and adverse effects were recorded for analysis.